Cree, B., Bennett, J., Kim, H., Weinshenker, B., Pittock, S., Wingerchuk, D., . . . Katz, E. (2019). Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2/3 trial. Elsevier.
Citace podle Chicago (17th ed.)Cree, BAC, et al. Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-blind, Randomised Placebo-controlled Phase 2/3 Trial. Elsevier, 2019.
Citace podle MLA (9th ed.)Cree, BAC, et al. Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-blind, Randomised Placebo-controlled Phase 2/3 Trial. Elsevier, 2019.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..